HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chemins

This article was originally published in The Tan Sheet

Executive Summary

Supplement maker is fined $2.3 mil. for failing to disclose use of ephedrine hydrochloride and caffeine anhydrous in products labeled "All Natural" under Denver federal court ruling July 7. Owner and president James Cameron receives same fine and is sentenced to 21 months in prison by Judge Walker Miller. The company and Cameron pleaded guilty in January to charges of conspiring to hide use of the substances from FDA. In exchange for the pleas, the U.S. attorney dismissed remaining charges stemming from Chemins' manufacture of Formula One supplements with ma huang and kola nut between December 1992 and June 1994 (1"The Tan Sheet" Oct. 25, 1999, p. 5)

You may also be interested in...



Chemins, Company Exec Indicted On Misbranding, Conspiracy Charges

The founder and president of Chemins, a Colorado-based dietary supplement manufacturer, is expected to enter a plea Nov. 8 on federal charges of product misbranding, conspiracy and obstructing FDA's investigation into the firm's alleged use of pharmaceutical-grade ephedrine and caffeine in its products.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel